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Heightened cutaneous immune surveillance in atopic 
patients may inhibit development of melanoma. The 
aim of this study was to analyse the association bet-
ween atopy and melanoma (development and outco-
me). A total of 188 cases of melanoma and 596 healthy 
controls were interviewed by telephone with a stan-
dardized questionnaire on atopic, demographic and 
melanoma characteristics. Cases were matched with 
controls on important confounders (age, sex, sunburn 
sensitivity, hair colour, number of moles, sunburn as 
juvenile, ever sunbed use, familial melanoma). Mela-
noma outcome data (disease relapse and death) within 
cases were retrieved. Analysis showed a general in-
verse association between atopy and melanoma deve-
lopment, but this was statistically significant only for a 
history of personal atopy (odds ratio 0.53, 95% confi-
dence interval: 0.30–0.96, p-value = 0.04). Among me-
lanoma patients, atopy did not affect survival or pro-
gression. In conclusion, this study suggests an inverse 
association between a history of atopy and melanoma 
development, but not with disease progression.
Key words: atopy; atopic dermatitis; case-control study; epide-
miology; melanoma; risk factors.
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Melanoma is the most frequent lethal form of cuta-neous malignancy among Caucasians. An increase 
in mortality rates and incidence rates of melanoma has 
been detected (1), whereby a further increase in incidence 
rates of melanoma in the coming years is forecasted (2). 
Melanoma accounts for approximately 75% of all skin 
cancer deaths, which translates into the loss of thousands 
of lives. In 2008, 45,000 deaths due to melanoma were 
reported worldwide (3). Although there are several novel 
treatment options for advanced melanoma currently un-
der investigation, mortality rates remain high. It has been 
hypothesized that a possible negative link between atopy 
and melanoma might exist due to the hyperactive im-
mune system in atopic patients, which might prevent the 
development of malignancy through increased immune 
surveillance (4, 5). Moreover, the fact that melanoma 
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is an immunogenic tumour might render this disease 
susceptible to the heightened immune surveillance in 
atopic patients (6). In addition, it has been shown that 
fewer naevi are present in patients with atopic dermati-
tis (AD), which implies that AD might protect against 
melanoma, since a high naevi count is a well-known risk 
factor for melanoma (7). However, atopy is an inflam-
matory disease, and inflammation has been linked with 
tumour development and has been postulated as one of 
the hallmarks of cancer. It has been hypothesized that 
inflammation can contribute to genetic instability and 
might even sustain a pro-oncogenic environment (4, 8).
To date, studies that have been conducted on the 
association between atopy and melanoma are scarce 
and contradictory. Three studies in large cohorts of 
subjects with AD have reported lower incidence ratios 
of melanoma cases in AD vs. non-AD populations (4, 
9, 10), while a recent study found a significant positive 
association between AD and melanoma (11). These 
studies examined the incidence of melanoma in AD vs. 
non-AD subjects, but did not take other melanoma risk 
factors into account. Three other studies comparing the 
incidence of AD in a melanoma case vs. a healthy control 
population, demonstrated a significant negative (12) and 
non-significant positive association (13) between mela-
noma and AD, but these studies also did not correct for 
melanoma risk factors, except for a recent Dutch study 
that corrected for phototype (14). To the best of our 
knowledge, none of the studies conducted on atopy and 
melanoma investigated the association between atopy 
and melanoma survival or progression.
Therefore, we sought to examine the association of 
atopy-related variables and melanoma development 
and progression in a case-control population, using a 
validated questionnaire for AD diagnosis, controlled for 
the major confounders of melanoma.
METHODS
Data collection
Cases and controls were recruited from March 2004 to January 
2008. Local ethics committees gave approval for the study (S 
number: 24960). A cohort of consecutive cutaneous patients with 
melanoma treated at the Department of Dermatology in University 
Hospitals Leuven and Antwerp University Hospital in Belgium 
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were informed about the aim (further insight in the cause of skin 
cancer and prevention of skin cancer) and content of the study 
(answering a questionnaire). They were also informed about the 
possible risks, the advantages of the study, the protection of their 
privacy, the right to information, and their right to withdraw from 
the study at any time. Two hundred and one consecutive mela-
noma cases were approached for the study. For each case, at least 
2 controls were selected from the same street (or residence area) 
using the telephone book. Both groups were interviewed via a te-
lephone call with a standardized questionnaire for the demographic 
data (age, sex and year of birth) and melanoma risk factors. The 
following major melanoma risk factors were registered: sunburn 
sensitivity (ability to burn after sun exposure in the beginning of 
the summer and after 1 h without sun protection), ability to tan 
(the ability to develop a tanned skin at the end of the summer after 
chronic sun exposure), natural hair colour, eye colour, number of 
moles, sunburn as juvenile, sunburn in the last 5 years, ever sunbed 
use, and presence of melanoma in first-degree family members 
were noted. Potential participants were given a schematic diagram 
along with the introduction letter for the study to instruct them 
how to assess their number of moles. For the ascertainment of 
AD, a questionnaire, namely the UK Working Party’s diagnostic 
criteria for AD was used (15) (Table I), which has been validated 
in several studies with a sensitivity of 80% and a specificity of 97% 
(16). Atopic dermatitis was defined as having an itchy skin plus 
at least 3 of the following criteria: itchy condition present before 
the age of 2 years, eczema on the elbows or knees, ankles, neck, 
around the eyes or ears, a history of asthma or hay fever and/or 
dry skin in the last year. The same questionnaire and 2 additional 
questions were used to define other atopy-related variables, namely 
personal atopy, respiratory atopy, active atopy and familial atopy 
(Table I). Personal atopy was defined as either having had AD or 
respiratory atopy. Respiratory atopy was defined as having had 
asthma or hay fever. Active atopy was defined as eczema (red, 
irritated, itchy rash) on the knees or elbow folds at the time of the 
interview. Familial atopy was positive when any of the siblings, 
children and/or parents ever had hay fever, eczema and/or asthma.
For the survival analyses, histopathological data and data on 
relapse date, date of last follow-up and date of death were collected 
from hospital records.
Statistical methods
The analyses consisted of 2 parts. First, we analyzed the possible 
correlation between atopy and presence of melanoma through 
comparison of the melanoma cases with the controls. Secondly, 
which concerns only the melanoma cases, the correlation bet-
ween atopy and outcome (progression-free survival (PFS) and 
overall survival (OS)) was evaluated. Descriptive statistics, 
such as Fisher’s exact and Mann-Whitney U tests, were used to 
evaluate distribution differences in characteristics between cases 
and controls with regard to demographic (age, sex) and major 
melanoma risk factors. A 1:1 matching was performed between 
cases and controls, matching for age, sex, and on all confounders 
found to be statistically significantly different between cases and 
controls in the descriptive analyses, more specifically sunburn 
sensitivity, tanning ability, natural hair colour, eye colour, number 
of moles, sunburn as juvenile, sunburn in the last 5 years, ever 
sunbed use, and presence of melanoma in first-degree family. 
Exact matches on the statistically significant confounders were 
made, except for age, where a maximal difference of 5 years has 
been allowed. Cases and controls within pairs were compared 
on atopy-related variables using exact McNemar’s tests. Condi-
tional logistic regression was used to calculate odds ratios (OR) 
and 95% confidence intervals (CI). Given that fewer naevi were 
seen in patients with AD, and that naevi count was the strongest 
predictor for melanoma risk amongst the potential confounders 
(i.e. highest area under the curve (AUC) in univariable analyses; 
results not shown), a sub-analysis was performed within the 
group with no/few naevi count. For the outcome analysis within 
the melanoma cases, histopathological data on relapse date, 
date of last follow-up and date of death were collected. Patients 
were followed from the time of diagnosis. The cut-off date for 
follow-up was 31 December 2014. Survival period was calculated 
from the time of diagnosis until the last follow-up visit if the 
patient was still alive, or until date of death. Any cause of death 
is considered an event for the OS and death due to melanoma 
for melanoma-related death (MRD). Progression-free period was 
calculated from time of diagnosis until date of progression or 
any cause of death or last follow-up. Cox proportional hazards 
models were used to analyse the association of atopy with OS, 
MRD and PFS. Due to the low number of events, corrections 
for the confounder’s age and staging were performed separately 
(referred to as bivariable models).
Significance level was set at p = 0.05. All tests were 2-sided. 
Analyses were performed in SAS (version 9.2 of the SAS System 
for Windows. Copyright 2002 SAS Institute Inc. SAS and all 
other SAS Institute Inc. product or service names are registered 
trademarks of SAS Institute Inc., Cary, NC, USA).
RESULTS
Out of the 1,058 healthy controls approached, there were 
237 refusals and 225 individuals could not be reached for 
the actual interview. A total of 596 controls were therefore 
included. Of the 201 cases contacted, there was 1 refusal, 
and 5 could not be contacted. Seven cases were excluded 
because the diagnosis of melanoma could not be con-
firmed on revision, leading to a final total of 188 cases.
Baseline characteristics found to be significantly as-
sociated with presence of melanoma in the univariate 
analyses were: age, sunburn sensitivity, hair colour, 
number of moles, sunburn as juvenile, sunbed use, and 
familial melanoma (Table II).
Matching cases with controls for age, sex, and the 
aforementioned 7 confounders resulted in a final total 
of 116 pairs. For all atopy-related variables, a negative 
association was found with the melanoma risk, i.e. the 
Table I. Questions used for the definition of the atopy-related 
variables and their definitions
UK Working Party’s diagnostic criteriaa
1. Have you ever had an itchy skin condition?
4. Have you ever had asthma [wheezing] or hay fever (sneezing, runny nose, 
itchy eyes in the summer)?
2. If yes, was this present before the age of two years?
3. Have you ever had eczema on the elbows or knees, ankles, neck, around 
the eyes or ears?
4. Have you ever had asthma [wheezing] or hay fever (sneezing, runny nose, 
itchy eyes in the summer)?
5. Have you had dry skin in the last 12 months?
Definitions
AD: question number 1=yes plus at least 3 other questions were answered yes
Personal atopy: if AD is present or question 4 was answered yes
Respiratory atopy: if question 4 was answered yes
Extra questions on
  Active AD: Do you currently have eczema (red, irritated, itchy rash) on the 
knee or elbow folds?
  Familial atopy: Have any of your siblings, children and/or parents ever had 
hay fever, eczema and/or asthma?
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prevalence was lower for the cases compared with the 
controls, resulting in ORs lower than 1 (Table III). 
However, only for personal atopy was this negative 
relation also significant (OR 0.53; 95% CI 0.30–0.96; 
p-value 0.04).
In the univariate analysis of the major confounders for 
melanoma risk, high naevus count was found to be the 
most important. Therefore, a sub-analysis in the group 
with no/few moles was conducted. This subgroup ana-
lysis on 79 pairs confirmed a relevant difference between 
cases and controls in personal atopy (29% vs. 13%, 
p = 0.03) and respiratory atopy (27% vs. 13%, p = 0.06) 
(detailed data not shown).
Cox analysis within the group of melanoma cases did 
not reveal a significant association between all atopy-re-
lated variables and PFS. The bivariable analysis, whereby 
a correction for staging or for age was conducted, did 
not alter the conclusions (Table IV). Also, for OS and 
melanoma-related death, no evidence was found for an 
association between atopy variables and outcome (data 
not shown).
DISCUSSION
In this clinically well characterized case-control popula-
tion, we found a significant negative association between 
personal atopy and melanoma development, while no 
significant associations were found between atopy and 
melanoma outcome.
A strength of this paper is the investigation of the 
relationship between atopy and melanoma development 
in a clinically well-characterized case-control popula-
tion. A huge effort had been made to minimize selection 
bias of controls by choosing healthy, unrelated controls. 
Another strength of this paper is the use of an exten-
sive questionnaire with which all major melanoma risk 
factors were meticulously registered, both in the mela-
noma population and control population. The study by 
Hajdarbegovic et al. (14) was the only previous study 
on melanoma and atopy that took account of phototype 
as confounder. Although phototype affects melanoma 





n (%) pa 
ORb  
(95% CI) pb 
Atopic dermatitis 11 (9.5)   5 (4.3) 0.21 
   Yes 0.46 (0.16; 1.31) 0.14 
   No Ref.
Personal atopy 35 (30.2) 20 (17.2) 0.04 
   Yes 0.53 (0.30; 0.96) 0.04 
   No Ref.
Respiratory atopy 32 (27.6) 19 (16.4) 0.07
   Yes 0.55 (0.30; 1.02) 0.06 
   No Ref.
Active atopy   5 (4.3)   2 (1.7) 0.45 
   Yes 0.40 (0.08; 2.06) 0.27 
   No Ref.
Familial atopy 58 (50.0) 52 (44.8) 0.52 
   Yes 0.82 (0.49; 1.36) 0.44 
   No Ref.
aMcNemar’s test results. bResults of the conditional logistic regression models. Odds 
ratio (OR) refers to the odds for being a case. CI: confidence interval.





HR (95% CI) p-value 
Bivariable results 
corrected for staging  





corrected for age 




Atopic dermatitis 166 (28) 1.49 (0.35; 6.30) 0.61 3.02 (0.69; 13.34) 0.20 2.01 (0.46; 8.80) 0.39 
Personal atopy 170 (29) 1.02 (0.41; 2.50) 0.97 1.05 (0.41; 2.69) 0.91 1.28 (0.51; 3.23) 0.61 
Respiratory atopy 173 (30) 1.09 (0.45; 2.68) 0.84 1.10 (0.43; 2.80) 0.84 1.37 (0.55; 3.41) 0.52 
Active atopy 173 (30) 0.00 (0.00; ND) 0.11 0.00 (0.00; ND) 0.21 0.00 (0.00; ND) 0.17 
Familial atopy 173 (30) 0.00 (0.00; ND) 0.11 0.00 (0.00; ND) 0.21 0.61 (0.28; 1.37) 0.22 
aResults of univariable and bivariable Cox regressions analyses, performed on the set of 173 melanoma cases with a median follow-up of 7 years. In the bivariable m 
odel, staging or age was added as a confounder. Since Wald tests are not valid in case there are no events for a specific level of the predictor, all reported p-values are 
obtained with likelihood-ratio tests (with 1 and 3 degrees of freedom for the effects of atopy and staging, respectively).
HR: Hazard ratio; ND: not defined; CI: confidence interval.
Table II. Baseline characteristics of the study populationa
Controls Cases p-value
Total, n 596 188
Age, years, mean 57.4 52.2 < 0.001
Sex, n 
  Male 224 69 0.863
  Female 372 119
Sunburn sensitivity, n
  Yes 440 163 < 0.001
  No 156 25
Tanning ability, n
  Brown/very brown 548 170 0.547
  Never/very mild 48 18
Hair colour, n
  Light 262 111 < 0.001
  Dark 332 77
Eye colour, n
  Light 438 143 0.700
  Dark 151 45
Moles, n
  No/few 498 107 < 0.001
  Multiple/many 81 78
Sunburn as juvenile, n
  No 354 83 < 0.001
  Yes 224 99
Sunburn last 5 years, n
  No 507 158 0.812
  Yes 85 28
Ever sunbed use, n
  No 315 69 < 0.001
  Yes 280 117
Familial melanoma (first-degree), n
  No 564 163 < 0.001
  Yes 4 23
aResults of univariate analysis of the differences in baseline characteristics be t-
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risk, it is not the only confounder, as demonstrated in 
this study.
When matched for important melanoma confounders 
(sunburn sensitivity, hair colour, number of moles, sun-
burn as juvenile, ever sunbed use, familial melanoma), 
age and sex, negative associations with melanoma de-
velopment were observed for all 5 variables referring 
to atopy. This observed inverse association between 
atopy and melanoma is in line with previous literature 
which also found a lower risk of melanoma in atopics 
(4, 9, 10, 12, 17). In our study the correlation was only 
significant for personal atopy and we have to acknow-
ledge that a strong claim about this correlation is not 
possible in the absence of a correction for multiple tes-
ting. Note that the power to detect differences between 
cases and controls depends on the prevalence, which 
differs strongly between the atopy-related variables. For 
example, in the matched analysis less than 5% of the 
controls have active atopy. To detect a significant reduc-
tion among the cases for this variable, a much larger 
study is required. Larger studies would help to further 
determine the nature of the link between melanoma 
and atopy. Another possible limitation is response bias. 
Although the response rate in the case group is high, 
that of the controls is not. It is probable that those who 
were contacted and had AD are more prone to cooperate 
if they think that there could be some personal benefit 
to be gained. It is also possible that recall bias might 
play a role in both groups. Recall bias might be present, 
since atopy tends to be more prominent at a young age. 
However, the case-control setting and random selection 
of controls should attenuate this bias. Also, the use of 
a validated questionnaire for AD diagnosis, whereby a 
combination of factors are taken into account before 
a positive diagnosis is made, might also reduce recall 
bias. The association between AD and melanoma OS, 
melanoma-related death, and recurrence-free survival 
were investigated, but this yielded no significant asso-
ciations. It could be that the higher immunosurveillance 
associated with atopy may protect against development 
of melanoma, but is not enough to protect against pro-
gression. In addition, lack of any association should be 
regarded with caution, since there were relatively few 
events in our study population. 
In summary, this study suggests an inverse correlation 
between personal atopy and melanoma development 
when matched for important confounders. In addition, 
no evidence has been found for an association between 
atopy and melanoma survival or progression.
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